<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26816607</article-id><article-id pub-id-type="pmc">4718094</article-id><article-id pub-id-type="doi">10.1111/jdi.12361</article-id><article-id pub-id-type="publisher-id">JDI12361</article-id><article-categories><subj-group subj-group-type="overline"><subject>Clinical Trial</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Science and Care</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy and safety of 40&#x000a0;mg or 60&#x000a0;mg duloxetine in <styled-content style="fixed-case">J</styled-content>apanese adults with diabetic neuropathic pain: Results from a randomized, 52&#x02010;week, open&#x02010;label study</article-title><alt-title alt-title-type="left-running-head">Yasuda <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12361-cr-0001" contrib-type="author" corresp="yes"><name><surname>Yasuda</surname><given-names>Hitoshi</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdi12361-cr-0002" contrib-type="author"><name><surname>Hotta</surname><given-names>Nigishi</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12361-cr-0003" contrib-type="author"><name><surname>Kasuga</surname><given-names>Masato</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jdi12361-cr-0004" contrib-type="author"><name><surname>Kashiwagi</surname><given-names>Atsunori</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jdi12361-cr-0005" contrib-type="author"><name><surname>Kawamori</surname><given-names>Ryuzo</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jdi12361-cr-0006" contrib-type="author"><name><surname>Yamada</surname><given-names>Tadaaki</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jdi12361-cr-0007" contrib-type="author"><name><surname>Baba</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jdi12361-cr-0008" contrib-type="author"><name><surname>Alev</surname><given-names>Levent</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jdi12361-cr-0009" contrib-type="author"><name><surname>Nakajo</surname><given-names>Ko</given-names></name><xref ref-type="aff" rid="jdi12361-aff-0007">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="jdi12361-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Faculty of Public Health Nursing</named-content><institution>Shiga University of Medical Science</institution><named-content content-type="city">Shiga</named-content><country country="JP">Japan</country></aff><aff id="jdi12361-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Japan Labor Health and Welfare Organization</named-content><institution>Chubu Rosai Hospital</institution><named-content content-type="city">Nagoya</named-content><country country="JP">Japan</country></aff><aff id="jdi12361-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Research Institute</named-content><institution>National Center for Global Health and Medicine</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="jdi12361-aff-0004"><label><sup>4</sup></label><institution>Kusatsu General Hospital</institution><named-content content-type="city">Shiga</named-content><country country="JP">Japan</country></aff><aff id="jdi12361-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Medicine, Metabolism &#x00026; Endocrinology</named-content><institution>Juntendo University Graduate School of Medicine</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="jdi12361-aff-0006"><label><sup>6</sup></label><institution>Shionogi &#x00026; Co., Ltd.</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="jdi12361-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Lilly Research Laboratories</named-content><institution>Eli Lilly Japan K.K.</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hitoshi Yasuda<break/>
Tel.: +81&#x02010;77&#x02010;587&#x02010;3588<break/>
Fax: +81&#x02010;77&#x02010;587&#x02010;5441<break/>
E&#x02010;mail address: <email>hyasuda@belle.shiga-med.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2016</year></pub-date><volume>7</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/jdi.2016.7.issue-1</issue-id><fpage>100</fpage><lpage>108</lpage><history><date date-type="received"><day>17</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>07</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>05</day><month>4</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDI-7-100.pdf"/><abstract abstract-type="main" id="jdi12361-abs-0001"><title>Abstract</title><sec id="jdi12361-sec-0001"><title>Introduction</title><p>To examine the long&#x02010;term efficacy and safety of duloxetine in the treatment of <styled-content style="fixed-case">J</styled-content>apanese patients with diabetic neuropathic pain, we carried out a 52&#x02010;week, randomized, open&#x02010;label extension of a 12&#x02010;week, double&#x02010;blind, placebo&#x02010;controlled study.</p></sec><sec id="jdi12361-sec-0002"><title>Materials and Methods</title><p>Japanese adults with diabetic neuropathic pain who completed the double&#x02010;blind study were eligible for this long&#x02010;term study, carried out at 71 sites in <styled-content style="fixed-case">J</styled-content>apan (<styled-content style="fixed-case">M</styled-content>arch 2008 to <styled-content style="fixed-case">M</styled-content>arch 2010). Participants (<italic>n</italic>&#x000a0;=&#x000a0;258) were re&#x02010;randomized (1:1) to 40&#x000a0;mg/day or 60&#x000a0;mg/day duloxetine. Pain (<styled-content style="fixed-case">B</styled-content>rief <styled-content style="fixed-case">P</styled-content>ain <styled-content style="fixed-case">I</styled-content>nventory severity and interference), quality of life (<styled-content style="fixed-case">P</styled-content>atient's <styled-content style="fixed-case">G</styled-content>lobal <styled-content style="fixed-case">I</styled-content>mpression of <styled-content style="fixed-case">I</styled-content>mprovement), and safety (primary outcome; adverse events, vital signs, metabolic measures) were measured.</p></sec><sec id="jdi12361-sec-0003"><title>Results</title><p>Significant (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and sustained improvements (change&#x000a0;&#x000b1;&#x000a0;standard deviation; <italic>n</italic>&#x000a0;=&#x000a0;257) were observed in <styled-content style="fixed-case">B</styled-content>rief <styled-content style="fixed-case">P</styled-content>ain <styled-content style="fixed-case">I</styled-content>nventory severity (average pain score &#x02212;2.1&#x000a0;&#x000b1;&#x000a0;1.7). Improvements were also seen in <styled-content style="fixed-case">B</styled-content>rief <styled-content style="fixed-case">P</styled-content>ain <styled-content style="fixed-case">I</styled-content>nventory interference (mean of subscores &#x02212;0.96&#x000a0;&#x000b1;&#x000a0;1.52) and <styled-content style="fixed-case">P</styled-content>atient's <styled-content style="fixed-case">G</styled-content>lobal <styled-content style="fixed-case">I</styled-content>mpression of <styled-content style="fixed-case">I</styled-content>mprovement (&#x02212;0.9&#x000a0;&#x000b1;&#x000a0;1.1) scores; these scores decreased significantly (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) during the long&#x02010;term study. Frequently reported adverse events included somnolence (13.6%), constipation (13.2%) and nausea (10.5%). Increases were observed in plasma glucose, glycosylated hemoglobin and total cholesterol levels, and in bodyweight and heart rate; however, none of these were clinically meaningful. Overall, there were no clinically significant safety concerns.</p></sec><sec id="jdi12361-sec-0004"><title>Conclusions</title><p>This is the first publication of a long&#x02010;term study carried out in <styled-content style="fixed-case">A</styled-content>sia with an entirely <styled-content style="fixed-case">J</styled-content>apanese patient population to suggest that long&#x02010;term duloxetine therapy for diabetic neuropathic pain is effective and has an acceptable safety profile.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jdi12361-kwd-0001">Diabetes&#x02010;related complications</kwd><kwd id="jdi12361-kwd-0002">Diabetic neuropathy (painful)</kwd><kwd id="jdi12361-kwd-0003">Duloxetine</kwd></kwd-group><funding-group><award-group><funding-source>Shionogi &#x00026; Co. Ltd</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly Japan K.K.</funding-source></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12361</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.5 mode:remove_FC converted:19.01.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jdi12361-cit-1001">
<source>J Diabetes Investig</source>
<year>2016</year>; <volume>7</volume>: <fpage>100</fpage>&#x02013;<lpage>108</lpage>
</mixed-citation>
</p></notes><notes><fn-group id="jdv12361-ntgp-2365"><fn id="jdi12361-note-0581"><p>
<bold>Clinical Trial Registry</bold>
</p><p>
<italic>ClinicalTrials.gov</italic>
</p><p>NCT00641719</p></fn></fn-group></notes></front><body><sec id="jdi12361-sec-0005"><title>Introduction</title><p>Diabetic peripheral neuropathy is a nerve disorder complication of diabetes, affecting up to 47% of patients with diabetes<xref rid="jdi12361-bib-0001" ref-type="ref">1</xref>. The socioeconomic burden of diabetic complications is increasing rapidly in Asia<xref rid="jdi12361-bib-0002" ref-type="ref">2</xref>, and Japan is expected to remain one of the top 10 countries worldwide for diabetes prevalence in 2030<xref rid="jdi12361-bib-0003" ref-type="ref">3</xref>. Up to 22% of patients with diabetes experience chronic diabetic neuropathic pain (DNP)<xref rid="jdi12361-bib-0004" ref-type="ref">4</xref>, <xref rid="jdi12361-bib-0005" ref-type="ref">5</xref>. Symptoms of DNP include aching, burning, tingling and stabbing sensations<xref rid="jdi12361-bib-0006" ref-type="ref">6</xref>, and the condition is associated with decreased quality of life, sleep impairment, anxiety and depression<xref rid="jdi12361-bib-0007" ref-type="ref">7</xref>, <xref rid="jdi12361-bib-0008" ref-type="ref">8</xref>, <xref rid="jdi12361-bib-0009" ref-type="ref">9</xref>. Pharmacological treatments for DNP focus on pain relief, and include tricyclic antidepressants, anticonvulsants and serotonin noradrenaline reuptake inhibitors<xref rid="jdi12361-bib-0010" ref-type="ref">10</xref>, <xref rid="jdi12361-bib-0011" ref-type="ref">11</xref>. However, the efficacy of some treatments can be compromised by adverse events, including cardiovascular complications, weight gain and hyperglycemia<xref rid="jdi12361-bib-0012" ref-type="ref">12</xref>, <xref rid="jdi12361-bib-0013" ref-type="ref">13</xref>, <xref rid="jdi12361-bib-0014" ref-type="ref">14</xref>.</p><p>Duloxetine, which selectively inhibits serotonin and noradrenaline reuptake from the central nervous system with relatively balanced affinity<xref rid="jdi12361-bib-0015" ref-type="ref">15</xref>, has shown promising efficacy and safety for the treatment of DNP<xref rid="jdi12361-bib-0016" ref-type="ref">16</xref>, <xref rid="jdi12361-bib-0017" ref-type="ref">17</xref>, <xref rid="jdi12361-bib-0018" ref-type="ref">18</xref>, <xref rid="jdi12361-bib-0019" ref-type="ref">19</xref>, <xref rid="jdi12361-bib-0020" ref-type="ref">20</xref>, <xref rid="jdi12361-bib-0021" ref-type="ref">21</xref>, <xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. Duloxetine provides relief from DNP<xref rid="jdi12361-bib-0016" ref-type="ref">16</xref>, <xref rid="jdi12361-bib-0017" ref-type="ref">17</xref>, <xref rid="jdi12361-bib-0019" ref-type="ref">19</xref>, <xref rid="jdi12361-bib-0023" ref-type="ref">23</xref>, and has been associated with improvements in quality of life<xref rid="jdi12361-bib-0019" ref-type="ref">19</xref> and cognitive function<xref rid="jdi12361-bib-0016" ref-type="ref">16</xref>. Both short&#x02010; and long&#x02010;term duloxetine treatment have been reported as having generally favorable safety profiles<xref rid="jdi12361-bib-0017" ref-type="ref">17</xref>, <xref rid="jdi12361-bib-0018" ref-type="ref">18</xref>, <xref rid="jdi12361-bib-0021" ref-type="ref">21</xref>, <xref rid="jdi12361-bib-0023" ref-type="ref">23</xref>, <xref rid="jdi12361-bib-0024" ref-type="ref">24</xref>. However, duloxetine treatment has been associated with changes in bodyweight, fasting blood glucose and glycosylated hemoglobin (HbA1c) levels, particularly after longer treatment<xref rid="jdi12361-bib-0019" ref-type="ref">19</xref>, <xref rid="jdi12361-bib-0025" ref-type="ref">25</xref>.</p><p>In Japan, duloxetine was approved for the treatment of DNP in February 2012, and was shown as being superior to placebo in a 12&#x02010;week, double&#x02010;blind, randomized, placebo&#x02010;controlled study of DNP in Japanese patients<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. The primary efficacy outcome of 24&#x02010;h average pain score was significantly improved for patients treated with duloxetine (40 or 60&#x000a0;mg/day) compared with placebo, and no clinically important safety concerns were noted<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. To examine long&#x02010;term duloxetine treatment in Japanese adults with DNP, we carried out a randomized, 52&#x02010;week, open&#x02010;label extension of that study. This is the first publication to present efficacy and safety (primary outcome) results from a long&#x02010;term study carried out in Asia with entirely Japanese patients.</p></sec><sec id="jdi12361-sec-0006"><title>Materials and Methods</title><sec id="jdi12361-sec-0007"><title>Study Design</title><p>This was a randomized, 52&#x02010;week, open&#x02010;label study (ClinicalTrials.gov no. NCT00641719) carried out at 71 sites from March 2008 to March 2010, which recruited participants who completed a 12&#x02010;week, multicenter, randomized, double&#x02010;blind, placebo&#x02010;controlled, parallel&#x02010;group, phase&#x000a0;3 study (NCT005&#x02010;52175)<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. Both studies were approved by the ethical review board at each site, and carried out in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and&#x000a0;all applicable laws and regulations. All participants provided written informed consent before any study&#x02010;related procedures.</p></sec><sec id="jdi12361-sec-0008"><title>Study Population</title><p>Participants who completed the double&#x02010;blind study and whose most recent HbA1c value was &#x02264;9.4% were invited to enrol in the long&#x02010;term study. As described previously<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>, the double&#x02010;blind study included Japanese adults with sustained pain for at least 6&#x000a0;months as a result of polyneuropathy caused by diabetes. All participants met the Diabetic Neuropathy Study Group of Japan criteria for diabetic peripheral neuropathy<xref rid="jdi12361-bib-0026" ref-type="ref">26</xref>. Individuals were excluded if they had a neurological disorder unrelated to diabetic peripheral neuropathy or a psychiatric disease, or if they were taking drug treatments other than acetaminophen or insulin.</p></sec><sec id="jdi12361-sec-0009"><title>Treatment Protocol</title><p>The protocol for the double&#x02010;blind study has been described elsewhere<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. Briefly, participants were randomized to receive duloxetine (Cymbalta<sup>&#x000ae;</sup>; Eli Lilly Japan K.K, Kobe, Japan, and Shionogi &#x00026; Co. Ltd, Osaka, Japan) or placebo for 12&#x000a0;weeks. In the long&#x02010;term study described here, all participants, regardless of treatment during the double&#x02010;blind study, were re&#x02010;randomized (1:1) to receive duloxetine 40&#x000a0;mg/day or 60&#x000a0;mg/day. Participants were re&#x02010;randomized using a stochastic minimization method taking into account the following factors from the double&#x02010;blind study: (i) treatment group; (ii) improvement in Brief Pain Inventory (BPI) severity &#x02013; average pain score of &#x0003e;30% or &#x0003c;30%; and (iii) investigational site.</p><p>The present long&#x02010;term study included tapering and treatment periods. Participants took duloxetine 20&#x000a0;mg/day during week&#x000a0;1, 40&#x000a0;mg/day during week&#x000a0;2, 40 or 60&#x000a0;mg/day (depending on treatment group) during weeks&#x000a0;3&#x02013;50, 40&#x000a0;mg/day during week&#x000a0;51 and 20&#x000a0;mg/day during week&#x000a0;52.</p><p>Study visits occurred biweekly during the first 4&#x000a0;weeks and every 4&#x000a0;weeks thereafter. Study visits also occurred at weeks&#x000a0;50 and 51 for the 60&#x000a0;mg/day and 40&#x000a0;mg/day treatment groups, respectively, before the final study visit at week&#x000a0;52 (or at discontinuation). Baseline was defined as the measurement obtained immediately before the start of duloxetine or placebo treatment in the double&#x02010;blind study. The study end&#x02010;point was the last available observation. The maximum duration of treatment with duloxetine was 52&#x000a0;weeks for participants who had received a placebo during the double&#x02010;blind study and 65&#x000a0;weeks for participants who had received duloxetine during both studies.</p></sec><sec id="jdi12361-sec-0010"><title>Efficacy Measures</title><p>The efficacy outcomes in this long&#x02010;term study were pain and quality of life. Pain was measured by the participant&#x02010;rated BPI severity (from 0 [no pain] to 10 [pain as bad as you can imagine]) and interference (from 0 [does not interfere] to 10 [completely interferes]) scales<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>, <xref rid="jdi12361-bib-0027" ref-type="ref">27</xref>. The BPI severity subscores included average pain, worst pain, least pain and current pain. The BPI interference scale measured patient functionalities, including general activity, mood, walking, work, relations with others, sleep, enjoyment of life and the mean of these seven items. Quality of life was also evaluated by the Patient's Global Impression of Improvement (PGI&#x02010;I) scale (from 1 [very much better] to 7 [very much worse])<xref rid="jdi12361-bib-0028" ref-type="ref">28</xref>.</p></sec><sec id="jdi12361-sec-0011"><title>Safety/Tolerability Measures</title><p>The primary outcome of the long&#x02010;term study was the safety/tolerability of duloxetine treatment. This was determined by the frequencies of adverse events (AEs), adverse drug reactions&#x000a0;(ADRs) and serious adverse events (SAEs), the rate of discontinuation as a result of AEs, and the severity of AEs (mild, moderate or severe). Events that occurred after the start of the long&#x02010;term study or that continued from the double&#x02010;blind study were counted as AEs. All AEs were coded and summarized using the Medical Dictionary for Regulatory Activities, Version 11.1. Adverse drug reactions were AEs judged by the investigator to be definitely related, probably related or possibly related to the study drug. The change from the start of the double&#x02010;blind study to the end of the long&#x02010;term study in metabolic measures (fasting plasma glucose, HbA1c, lipid profile), vital signs (heart rate, systolic blood pressure, diastolic blood pressure), bodyweight and electrocardiogram (defined as normal, borderline or abnormal by the investigator) were also determined. HbA1c was measured according to recommendations from the Japanese Diabetes Society (JDS) and converted to National Glycohemoglobin Standardization Program (NGSP) equivalent values (NGSP %HbA1c&#x000a0;=&#x000a0;[1.02&#x000a0;&#x000d7;&#x000a0;JDS %HbA1c]&#x000a0;+&#x000a0;0.25%)<xref rid="jdi12361-bib-0029" ref-type="ref">29</xref>.</p></sec><sec id="jdi12361-sec-0012"><title>Statistical Analysis</title><p>Participants were included in the efficacy analysis if they had at least one assessment after the start of the long&#x02010;term study, and in the safety analysis if they had taken at least one dose of duloxetine. Efficacy results were also stratified by treatment group in the previous double&#x02010;blind study. Values for mean and standard deviation (SD) were calculated for efficacy measures, laboratory measures, and vital signs. Summary statistics were calculated for the change from the start of the double&#x02010;blind study (vital signs, metabolic measures, bodyweight) or from the start of the long&#x02010;term study (efficacy measures) to the last observation during treatment. Changes in efficacy and laboratory measures were analyzed by Wilcoxon's signed&#x02010;rank test. Statistical significance was set at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05. Analyses were carried out using SAS<sup>&#x000ae;</sup> Version 9.1.3 (SAS Institute Inc, Cary, NC, USA).</p></sec></sec><sec id="jdi12361-sec-0013"><title>Results</title><sec id="jdi12361-sec-0014"><title>Participant Disposition and Characteristics</title><p>In the double&#x02010;blind study, 448 potential participants were screened, 339 were randomized and 293 completed the study (Figure&#x000a0;<xref rid="jdi12361-fig-0001" ref-type="fig">1</xref>)<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. A total of 258 participants enrolled in the long&#x02010;term study, and were re&#x02010;randomized to receive duloxetine 40&#x000a0;mg/day (129 participants) or 60&#x000a0;mg/day (129 participants; Figure&#x000a0;<xref rid="jdi12361-fig-0001" ref-type="fig">1</xref>). A total of 99 (77%) and 91 (71%) participants in the 40&#x000a0;mg/day and 60&#x000a0;mg/day groups, respectively, completed the long&#x02010;term study. The characteristics of participants in each group in the long&#x02010;term study were broadly similar (Table&#x000a0;<xref rid="jdi12361-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="jdi12361-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Participant demographics and characteristics at baseline</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="top" rowspan="1" colspan="1">Duloxetine 40&#x000a0;mg/day (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="center" valign="top" rowspan="1" colspan="1">Duloxetine 60&#x000a0;mg/day (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="center" valign="top" rowspan="1" colspan="1">Combined Duloxetine (<italic>n</italic>&#x000a0;=&#x000a0;258)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean age (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">60.2&#x000a0;&#x000b1;&#x000a0;10.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">60.0&#x000a0;&#x000b1;&#x000a0;9.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">60.1&#x000a0;&#x000b1;&#x000a0;10.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">89 (69.0)</td><td align="char" char=" " rowspan="1" colspan="1">107 (82.9)</td><td align="char" char=" " rowspan="1" colspan="1">196 (76.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean weight (kg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63.9&#x000a0;&#x000b1;&#x000a0;12.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65.0&#x000a0;&#x000b1;&#x000a0;11.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.5&#x000a0;&#x000b1;&#x000a0;11.8</td></tr><tr><td align="left" colspan="4" rowspan="1">Duration of diabetes, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;5&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">23 (17.8)</td><td align="char" char=" " rowspan="1" colspan="1">25 (19.4)</td><td align="char" char=" " rowspan="1" colspan="1">48 (18.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">5&#x02013;10&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">27 (20.9)</td><td align="char" char=" " rowspan="1" colspan="1">23 (17.8)</td><td align="char" char=" " rowspan="1" colspan="1">50 (19.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;10&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">76 (58.9)</td><td align="char" char=" " rowspan="1" colspan="1">79 (61.2)</td><td align="char" char=" " rowspan="1" colspan="1">155 (60.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unknown</td><td align="char" char=" " rowspan="1" colspan="1">3 (2.3)</td><td align="char" char=" " rowspan="1" colspan="1">2 (1.6)</td><td align="char" char=" " rowspan="1" colspan="1">5 (1.9)</td></tr><tr><td align="left" colspan="4" rowspan="1">Type of diabetes, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type&#x000a0;1</td><td align="char" char=" " rowspan="1" colspan="1">8 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (3.1)</td><td align="char" char=" " rowspan="1" colspan="1">12 (4.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type&#x000a0;2</td><td align="char" char=" " rowspan="1" colspan="1">121 (93.8)</td><td align="char" char=" " rowspan="1" colspan="1">125 (96.9)</td><td align="char" char=" " rowspan="1" colspan="1">246 (95.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean duration of DPN (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.9&#x000a0;&#x000b1;&#x000a0;3.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.3&#x000a0;&#x000b1;&#x000a0;3.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.1&#x000a0;&#x000b1;&#x000a0;3.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean HbA1c (%)<xref ref-type="fn" rid="jdi12361-note-0001">a</xref>
</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.02&#x000a0;&#x000b1;&#x000a0;0.93</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.17&#x000a0;&#x000b1;&#x000a0;0.87</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.09&#x000a0;&#x000b1;&#x000a0;0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean plasma glucose (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">145.5&#x000a0;&#x000b1;&#x000a0;57.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">148.7&#x000a0;&#x000b1;&#x000a0;61.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">147.1&#x000a0;&#x000b1;&#x000a0;59.5</td></tr></tbody></table><table-wrap-foot><fn id="jdi12361-note-0001"><label>a</label><p>Glycosylated hemoglobin (HbA1c) was measured according to recommendations from the Japanese Diabetes Society and converted to National Glycohemoglobin Standardization Program equivalent values (%HbA1c&#x000a0;=&#x000a0;[1.02&#x000a0;&#x000d7;&#x000a0;Japanese Diabetes Society %HbA1c]&#x000a0;+&#x000a0;0.25%)<xref rid="jdi12361-bib-0029" ref-type="ref">29</xref>. DPN, diabetic peripheral neuropathy; HbA1c, glycosylated hemoglobin; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jdi12361-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Participant flow diagram for the double&#x02010;blind (<styled-content style="fixed-case">DB</styled-content>) and open&#x02010;label extension (<styled-content style="fixed-case">OLE</styled-content>) studies. &#x02020;One participant did not receive any study drug and was not assessed at any study visits after the start of the double&#x02010;blind study; this participant was excluded from the analysis. &#x02021;One participant discontinued during the taper phase, not the treatment phase. <styled-content style="fixed-case">AE</styled-content>, adverse event.</p></caption><graphic id="nlm-graphic-3" xlink:href="JDI-7-100-g001"/></fig></sec><sec id="jdi12361-sec-0015"><title>Efficacy Outcome Measures</title><sec id="jdi12361-sec-0016"><title>Pain</title><p>The severity of pain, as rated by participants, and the interference caused by that pain, improved during this long&#x02010;term study. The BPI severity &#x02013; average pain score and all other pain subscores improved significantly (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) from the start of the long&#x02010;term study to the end&#x02010;point (Figure&#x000a0;<xref rid="jdi12361-fig-0002" ref-type="fig">2</xref>; Table S1). The BPI severity &#x02013; average pain score decreased from the first week of the study (potentially because some participants had received a placebo in the previous double&#x02010;blind study) and continued to decline throughout the study period (Figure&#x000a0;<xref rid="jdi12361-fig-0003" ref-type="fig">3</xref>). Changes in the other BPI severity and interference subscores followed a similar time&#x02010;course (data not shown). There was no difference between the 40&#x000a0;mg/day and 60&#x000a0;mg/day groups for any BPI measurement of pain severity subscores (Table S1). However, there were greater improvements in most, but not all, measures of BPI severity in participants who had received a placebo in the previous double&#x02010;blind study compared with participants who had received duloxetine (Table S1).</p><fig fig-type="Figure" xml:lang="en" id="jdi12361-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean (&#x000b1;standard deviation) change from the start of the long&#x02010;term study in <styled-content style="fixed-case">B</styled-content>rief <styled-content style="fixed-case">P</styled-content>ain <styled-content style="fixed-case">I</styled-content>nventory (<styled-content style="fixed-case">BPI</styled-content>) severity &#x02013; average pain score, <styled-content style="fixed-case">P</styled-content>atient's <styled-content style="fixed-case">G</styled-content>lobal <styled-content style="fixed-case">I</styled-content>mpression of <styled-content style="fixed-case">I</styled-content>mprovement (<styled-content style="fixed-case">PGI</styled-content>&#x02010;<styled-content style="fixed-case">I</styled-content>) score and <styled-content style="fixed-case">BPI</styled-content> interference subscores at the end of the long&#x02010;term study. Results from the combined duloxetine group (40&#x000a0;mg/day and 60&#x000a0;mg/day, <italic>n</italic>&#x000a0;=&#x000a0;257) are presented. All scores decreased significantly from the start of the long&#x02010;term study (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 for all scores; <styled-content style="fixed-case">W</styled-content>ilcoxon's signed&#x02010;rank test).</p></caption><graphic id="nlm-graphic-5" xlink:href="JDI-7-100-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="jdi12361-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mean (&#x000b1;standard deviation) change in <styled-content style="fixed-case">B</styled-content>rief <styled-content style="fixed-case">P</styled-content>ain <styled-content style="fixed-case">I</styled-content>nventory (<styled-content style="fixed-case">BPI</styled-content>) severity &#x02013; average pain scores during the long&#x02010;term study (50/51&#x000a0;weeks). Results from the combined duloxetine group (40&#x000a0;mg/day and 60&#x000a0;mg/day, <italic>n</italic>&#x000a0;=&#x000a0;191&#x02013;258) are presented.</p></caption><graphic id="nlm-graphic-7" xlink:href="JDI-7-100-g003"/></fig></sec><sec id="jdi12361-sec-0017"><title>Quality of Life</title><p>Patient functionality was assessed by BPI interference scores. All BPI interference subscores decreased significantly from the start of the long&#x02010;term study, showing improvements in general activity, mood, walking, work, relations with others, sleep and enjoyment of life (Figure&#x000a0;<xref rid="jdi12361-fig-0002" ref-type="fig">2</xref>), and continued to decline throughout the study period. All changes in BPI interference scores were similar regardless of treatment group in the double&#x02010;blind study (Table S1). The quality of life of participants was mainly measured by PGI&#x02010;I (Figure&#x000a0;<xref rid="jdi12361-fig-0002" ref-type="fig">2</xref>). The PGI&#x02010;I scores significantly (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) decreased from the start of the long&#x02010;term study and continued to decline slowly throughout the study. There was no difference between the 40&#x000a0;mg/day and 60&#x000a0;mg/day groups (Table S1). However, there were greater improvements in PGI&#x02010;I in participants who had received a placebo in the previous double&#x02010;blind study compared with participants who had received duloxetine (Table S1). In addition, the proportion of participants reporting improvements in quality of life increased during the long&#x02010;term study (Figure&#x000a0;<xref rid="jdi12361-fig-0004" ref-type="fig">4</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jdi12361-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Proportion of participants at each <styled-content style="fixed-case">P</styled-content>atient's <styled-content style="fixed-case">G</styled-content>lobal <styled-content style="fixed-case">I</styled-content>mpression of <styled-content style="fixed-case">I</styled-content>mprovement (<styled-content style="fixed-case">PGI</styled-content>&#x02010;<styled-content style="fixed-case">I</styled-content>) scale level at the start (<italic>n</italic>&#x000a0;=&#x000a0;258) and at the end of the long&#x02010;term study (last observation carried forward; <italic>n</italic>&#x000a0;=&#x000a0;257). Results from the combined duloxetine group (40&#x000a0;mg/day and 60&#x000a0;mg/day) are presented.</p></caption><graphic id="nlm-graphic-9" xlink:href="JDI-7-100-g004"/></fig></sec></sec><sec id="jdi12361-sec-0018"><title>Safety and Tolerability</title><sec id="jdi12361-sec-0019"><title>Incidence of Adverse Events</title><p>Most participants (248/258; 96.1%) in the present long&#x02010;term study experienced an AE. As in the double&#x02010;blind study<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>, there was no significant difference in the incidence of AEs between the 40&#x000a0;mg/day (126/129; 97.7%) and 60&#x000a0;mg/day (122 of 129; 94.6%) groups. Overall, 54 (20.9%) of 258 participants in the long&#x02010;term study discontinued because of an AE (Figure&#x000a0;<xref rid="jdi12361-fig-0001" ref-type="fig">1</xref>); one of these participants (60&#x000a0;mg/day group) discontinued during the taper phase (i.e., after finishing the full dose), not during the treatment phase.</p><p>In the present long&#x02010;term study, there were 12 SAEs in 11 participants in the 40&#x000a0;mg/day group and 34 SAEs in 22 participants in the 60&#x000a0;mg/day group. One participant in the 40&#x000a0;mg/day group died as a result of myocardial ischemia, which was considered unrelated to treatment. There were 11 ADRs in the long&#x02010;term study: cerebral infarction, lymphoma and colon cancer in the 40&#x000a0;mg/day group, and generalized edema, cardiac failure, clavicle fracture, thoracic vertebral fracture, spinal compression fracture, lung injury, pneumothorax and gastric cancer in the 60&#x000a0;mg/day group.</p></sec><sec id="jdi12361-sec-0020"><title>Common Adverse Events</title><p>In the previous double&#x02010;blind study, several AEs occurred in at least 5% of duloxetine&#x02010;treated participants, and were at least twice as common in these participants than in placebo&#x02010;treated participants. These AEs included the symptoms somnolence, nausea, dizziness, malaise and vomiting, and the laboratory measures increased aspartate aminotransferase and increased white blood cell count<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. The incidence of these AEs during the long&#x02010;term study (Table&#x000a0;<xref rid="jdi12361-tbl-0002" ref-type="table-wrap">2</xref>) was generally similar to the incidence during the double&#x02010;blind study<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>. Other common AEs during the long&#x02010;term study, experienced by &#x0003e;10% of participants, were nasopharyngitis (67 participants; 26.0%), increased HbA1c (60; 23.3%), constipation (34; 13.2%), increased blood glucose (26; 10.1%) and hypoglycemia (26; 10.1%). Only one participant experienced nasopharyngitis that was possibly related to the study drug. The incidence of these AEs during the double&#x02010;blind study was similar in both the duloxetine and placebo groups<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>.</p><table-wrap id="jdi12361-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Incidence of adverse events during the long&#x02010;term study</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Preferred term<xref ref-type="fn" rid="jdi12361-note-0002">a</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">Duloxetine 40&#x000a0;mg/day (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="center" valign="top" rowspan="1" colspan="1">Duloxetine 60&#x000a0;mg/day (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="center" valign="top" rowspan="1" colspan="1">Combined Duloxetine (<italic>n</italic>&#x000a0;=&#x000a0;258)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Symptoms</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Somnolence</td><td align="char" char=" " rowspan="1" colspan="1">
17 (17)<break/>
13.2%
</td><td align="char" char=" " rowspan="1" colspan="1">
18 (18)<break/>
14.0%
</td><td align="char" char=" " rowspan="1" colspan="1">
35 (35)<break/>
13.6%
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nausea</td><td align="char" char=" " rowspan="1" colspan="1">
14 (16)<break/>
10.9%
</td><td align="char" char=" " rowspan="1" colspan="1">
13 (15)<break/>
10.1%
</td><td align="char" char=" " rowspan="1" colspan="1">
27 (31)<break/>
10.5%
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dizziness</td><td align="char" char=" " rowspan="1" colspan="1">
10 (12)<break/>
7.8%
</td><td align="char" char=" " rowspan="1" colspan="1">
8 (11)<break/>
6.2%
</td><td align="char" char=" " rowspan="1" colspan="1">
18 (23)<break/>
7.0%
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Malaise</td><td align="char" char=" " rowspan="1" colspan="1">
6 (6)<break/>
4.7%
</td><td align="char" char=" " rowspan="1" colspan="1">
5 (5)<break/>
3.9%
</td><td align="char" char=" " rowspan="1" colspan="1">
11 (11)<break/>
4.3%
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vomiting</td><td align="char" char=" " rowspan="1" colspan="1">
9 (11)<break/>
7.0%
</td><td align="char" char=" " rowspan="1" colspan="1">
10 (12)<break/>
7.8%
</td><td align="char" char=" " rowspan="1" colspan="1">
19 (23)<break/>
7.4%
</td></tr><tr><td align="left" colspan="4" rowspan="1">Laboratory measures</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">AST increased</td><td align="char" char=" " rowspan="1" colspan="1">
13 (13)<break/>
10.1%
</td><td align="char" char=" " rowspan="1" colspan="1">
12 (14)<break/>
9.3%
</td><td align="char" char=" " rowspan="1" colspan="1">
25 (27)<break/>
9.7%
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">WBC count increased</td><td align="char" char=" " rowspan="1" colspan="1">
13 (16)<break/>
10.1%
</td><td align="char" char=" " rowspan="1" colspan="1">
8 (8)<break/>
6.2%
</td><td align="char" char=" " rowspan="1" colspan="1">
21 (24)<break/>
8.1%
</td></tr></tbody></table><table-wrap-foot><fn id="jdi12361-note-0002"><label>a</label><p>According to the Medical Dictionary for Regulatory Activities, Version 11.1. AST, aspartate aminotransferase; WBC, white blood cell.</p></fn><fn id="jdi12361-note-0003"><p>Data are presented as number of participants, (number of events), and percentage incidence. The table presents events that were experienced by at least 5% of participants in any group during the double&#x02010;blind study and were at least twice as common in the combined duloxetine group compared with the placebo group<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Most AEs were mild (824/1,914; 43.1%) or moderate (1,055/1,914; 55.1%) in severity and occurred during the first week of treatment (data not shown). The proportion of moderate AEs was somewhat higher in the long&#x02010;term study than in the double&#x02010;blind study (30.3%)<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>.</p></sec><sec id="jdi12361-sec-0021"><title>Vital Signs and Metabolic Measures</title><p>Vital signs and metabolic measures were assessed from the start of the double&#x02010;blind study (baseline) to the end of the long&#x02010;term study. There were no clinically significant changes in vital signs, electrocardiogram or bodyweight. There were small, but statistically significant, increases in heart rate (mean change +2.6&#x000a0;b.p.m.; <italic>n</italic>&#x000a0;=&#x000a0;242; <italic>P</italic>&#x000a0;=&#x000a0;0.0009) and bodyweight (mean change, +1.4&#x000a0;kg; <italic>n</italic>&#x000a0;=&#x000a0;241; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). There was a significant increase in HbA1c (mean [25th percentile, 75th percentile]) from baseline to end&#x02010;point (change +0.45% [&#x02212;0.10, 0.92]; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; <italic>n</italic>&#x000a0;=&#x000a0;240). There were also significant increases (mean [25th percentile, 75th percentile]) in plasma glucose (+18.4 [&#x02212;19.5, 59.0]&#x000a0;mg/dL; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), total cholesterol (+6.4 [&#x02212;11.0, 29.0]&#x000a0;mg/dL; <italic>P</italic>&#x000a0;=&#x000a0;0.0004), and low&#x02010;density lipoprotein cholesterol (+2.1 [&#x02212;11.0, 19.0] mg/dL; <italic>P</italic>&#x000a0;=&#x000a0;0.0439; <italic>n</italic>&#x000a0;=&#x000a0;240 for all measures). There were no significant changes in high&#x02010;density lipoprotein cholesterol or triglycerides.</p></sec></sec></sec><sec id="jdi12361-sec-0022"><title>Discussion</title><p>This is the first publication of a long&#x02010;term (52&#x02010;week), randomized, open&#x02010;label study carried out in Asia entirely in Japanese patients that evaluated the efficacy and safety of duloxetine in adults with DNP. Long&#x02010;term duloxetine treatment was associated with sustained improvements in pain severity, consistent with findings from other studies. For example, 6&#x000a0;months of duloxetine treatment in Caucasian participants with DNP was associated with improvements in BPI severity and the Clinical Global Impression of Severity scores<xref rid="jdi12361-bib-0030" ref-type="ref">30</xref>. Although that study was shorter than the present long&#x02010;term study, the improvement in pain was similar. Together, these studies suggest that duloxetine continues to be analgesic over the long term in patients with DNP. Notably, the improvement in pain during our long&#x02010;term study was observed regardless of the treatment participants had received during the double&#x02010;blind study.</p><p>Patients with DNP typically have impaired quality of life, which might be related to the extent and severity of pain<xref rid="jdi12361-bib-0008" ref-type="ref">8</xref>. Participants in the present study reported improved quality of life after long&#x02010;term duloxetine treatment, consistent with a 12&#x02010;month study in Caucasian patients (in which quality of life was assessed using the 36&#x02010;Item Short Form Health Survey and European Quality of Life Instrument&#x02010;5D)<xref rid="jdi12361-bib-0023" ref-type="ref">23</xref>. Participants in our study also reported significant improvements in BPI interference, an indirect measure of quality of life. Although the improvements in interference were smaller than those in a 6&#x02010;month study<xref rid="jdi12361-bib-0030" ref-type="ref">30</xref>, the present study used lower doses of duloxetine than the shorter study (120&#x000a0;mg/day). We believe the improvements in pain severity and interference experienced by the present study participants contributed to a sustained improvement in quality of life.</p><p>Our findings show that duloxetine has an acceptable safety and tolerability profile in Japanese adults with DNP, consistent with findings from long&#x02010;term studies in Caucasians<xref rid="jdi12361-bib-0023" ref-type="ref">23</xref>, <xref rid="jdi12361-bib-0024" ref-type="ref">24</xref>. The incidence of AEs was relatively high in both the previous double&#x02010;blind study<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref> and the current long&#x02010;term study, again consistent with previous studies<xref rid="jdi12361-bib-0018" ref-type="ref">18</xref>, <xref rid="jdi12361-bib-0021" ref-type="ref">21</xref>, <xref rid="jdi12361-bib-0023" ref-type="ref">23</xref>, <xref rid="jdi12361-bib-0024" ref-type="ref">24</xref>, <xref rid="jdi12361-bib-0025" ref-type="ref">25</xref>. However, the rate of discontinuation as a result of an AE in our long&#x02010;term study (20.9%) was greater than that among duloxetine&#x02010;treated participants in both the 12&#x02010;week, double&#x02010;blind study (12.2%)<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref> and in other 52&#x02010;week studies (5.6%<xref rid="jdi12361-bib-0023" ref-type="ref">23</xref> and 9.3%<xref rid="jdi12361-bib-0024" ref-type="ref">24</xref>). This result suggests that Japanese patients might be more inclined to discontinue as a result of AEs during long&#x02010;term duloxetine treatment. However, <italic>post&#x02010;hoc</italic> analyses of data from the double&#x02010;blind study show that the most common AEs experienced by duloxetine&#x02010;treated participants were not persistent. The majority (77.6%) of somnolence, nasopharyngitis and nausea occurrences resolved during the 12&#x02010;week study, with mean (&#x000b1;SD) durations of 22.6&#x000a0;&#x000b1;&#x000a0;27.1&#x000a0;days, 14.7&#x000a0;&#x000b1;&#x000a0;12.4&#x000a0;days and 10.8&#x000a0;&#x000b1;&#x000a0;13.2&#x000a0;days, respectively.</p><p>As noted, there were no significant or remarkable differences between dose groups in the efficacy or safety of duloxetine in the present long&#x02010;term study. Given the similar efficacy between the dose groups, the recommended optimal dose of duloxetine for the treatment of DNP in Japanese patients is considered to be the lower dose of 40&#x000a0;mg/day, at least for 1&#x000a0;year of the dosing period. However, if efficacy is insufficient, the dose might be increased to 60&#x000a0;mg/day with minimal additional risk of adverse events.</p><p>In the present study, long&#x02010;term duloxetine treatment was associated with changes in metabolic measures, particularly HbA1c and blood glucose, which were greater than those reported for other 52&#x02010;week studies of duloxetine<xref rid="jdi12361-bib-0023" ref-type="ref">23</xref>, <xref rid="jdi12361-bib-0024" ref-type="ref">24</xref>. However, the observed increase in HbA1c (0.45%) was below the level at which a clinically meaningful change is likely (0.5%)<xref rid="jdi12361-bib-0031" ref-type="ref">31</xref>. The increase in HbA1c in the long&#x02010;term study contrasts with that of the 12&#x02010;week, double&#x02010;blind study (placebo 0.10%; duloxetine 0.06%)<xref rid="jdi12361-bib-0022" ref-type="ref">22</xref>, suggesting that weekly visits during the double&#x02010;blind study might have provided a better opportunity to control participants&#x02019; diabetes than the monthly visits during the long&#x02010;term study. In addition, increased HbA1c is generally associated with long&#x02010;term, rather than short&#x02010;term, duloxetine treatment<xref rid="jdi12361-bib-0025" ref-type="ref">25</xref>, and could result from progression of diabetes rather than from duloxetine treatment itself. Similarly, the bodyweight changes in our long&#x02010;term study were consistent with changes seen in other long&#x02010;term duloxetine studies<xref rid="jdi12361-bib-0025" ref-type="ref">25</xref>, <xref rid="jdi12361-bib-0032" ref-type="ref">32</xref>, and, like HbA1c, could be related to diabetes progression rather than duloxetine.</p><p>Management of elderly patients with DNP can be complicated by comorbidities and concomitant medications, and the safety and tolerability of some treatments are of particular concern in this population<xref rid="jdi12361-bib-0033" ref-type="ref">33</xref>. To examine the efficacy and safety of duloxetine in the elderly population, we carried out subgroup analyses of data from the double&#x02010;blind study. Among elderly participants (aged &#x02265;65&#x000a0;years), the improvement in 24&#x02010;h average pain score was significantly greater (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) in those treated with duloxetine (<italic>n</italic>&#x000a0;=&#x000a0;62) than in those treated with placebo (<italic>n</italic>&#x000a0;=&#x000a0;53). Furthermore, the incidence of AEs among elderly participants was similar to that of the overall study population, and no SAEs occurred in this subgroup. Together with the results of other studies<xref rid="jdi12361-bib-0033" ref-type="ref">33</xref>, these results suggest that duloxetine might be an effective and well&#x02010;tolerated option for the treatment of elderly patients with DNP, including those from Asia.</p><p>The present study is strengthened by the duration of treatment, the involvement of multiple study centers and the exclusive enrolment of Japanese participants with DNP, which allowed evaluation of long&#x02010;term duloxetine treatment for the first time in an Asian population. In addition, participants with psychiatric diseases requiring pharmacotherapy were excluded, thereby controlling for the potential confounding effects of treatment with antidepressants. However, the open&#x02010;label design and lack of placebo or routine care control group are limitations of the long&#x02010;term study. Also, because participants were re&#x02010;randomized in the long&#x02010;term study, the participants&#x02019; total exposure to duloxetine varied.</p><p>In conclusion, the present findings suggest that duloxetine is an effective long&#x02010;term therapy with an acceptable safety and tolerability profile in Japanese patients with DNP. Given that all treatments for DNP are symptomatic only<xref rid="jdi12361-bib-0011" ref-type="ref">11</xref>, duloxetine could be a suitable long&#x02010;term treatment option, because it was associated with improvements in both pain severity and the quality of life of patients.</p></sec><sec id="jdi12361-sec-1023"><title>Disclosure</title><p>HY has received research funding, consultancy fees, and speaker fees from Shionogi &#x00026; Co. Ltd and Eli Lilly Japan K.K. NH has received consultancy fees and speaker fees from Shionogi &#x00026; Co. Ltd and Eli Lilly Japan K.K. MK has received research funding, consultancy fees, and speaker fees from Shionogi &#x00026; Co. Ltd and Eli Lilly Japan K.K. AK has received research funding, consultancy fees, and speaker fees from Shionogi &#x00026; Co. Ltd and Eli Lilly Japan K.K. RK has received research funding, consultancy fees, and speaker fees from Shionogi &#x00026; Co. Ltd and Eli Lilly Japan K.K. TY and YB are employees of Shionogi &#x00026; Co. Ltd. LA and KN are employees of Eli Lilly Japan K.K.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Table S1</bold> &#x000a6; Change in efficacy measures from the start of the long&#x02010;term study to the end of treatment (overall and stratified by treatment group during the double&#x02010;blind study).</p></caption><media xlink:href="JDI-7-100-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jdi12361-sec-0023"><title>Acknowledgments</title><p>The authors are deeply grateful to the 84 primary investigators, subinvestigators and staff at the 73 study sites, and all the patients who participated in this study. This study was sponsored by Eli Lilly Japan K.K, the licensee, with Shionogi &#x00026; Co. Ltd, of Cymbalta<sup>&#x000ae;</sup> in Japan. In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study's results. Medical writing assistance was provided by Rebecca Lew, PhD, CMPP, and Janelle Keys, PhD, of ProScribe &#x02013; part of the Envision Pharma Group, funded by Eli Lilly Japan K.K. ProScribe's services complied with international guidelines for Good Publication Practice (GPP2). Eli Lilly Japan K.K. and Shionogi &#x00026; Co. Ltd were involved in the study design, data collection, data analysis, and preparation of the manuscript.</p></ack><ref-list content-type="cited-references" id="jdi12361-bibl-0001"><title>References</title><ref id="jdi12361-bib-0001"><label>1</label><mixed-citation publication-type="journal">
<string-name>
<surname>Barrett</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Lucero</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>T</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review</article-title>. <source>Pain Med</source>
<year>2007</year>; <volume>8</volume>(<issue>Suppl 2</issue>): <fpage>S50</fpage>&#x02013;<lpage>S62</lpage>.<pub-id pub-id-type="pmid">17714116</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0002"><label>2</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chan</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Deerochanawong</surname>
<given-names>C</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't know</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2011</year>; <volume>94</volume>: <fpage>1</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">21742396</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0003"><label>3</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wild</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Roglic</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Global prevalence of diabetes: estimates for the year 2000 and projections for 2030</article-title>. <source>Diabetes Care</source>
<year>2004</year>; <volume>27</volume>: <fpage>1047</fpage>&#x02013;<lpage>1053</lpage>.<pub-id pub-id-type="pmid">15111519</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0004"><label>4</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hanaoka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hotta</surname>
<given-names>N</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Current status of neuropathic pain treatment in Japan and scope in future &#x02013; proposal from the consensus conference of specialists</article-title>. <source>Pain Clinic</source>
<year>2009</year>; <volume>30</volume>: <fpage>1395</fpage>&#x02013;<lpage>1408</lpage> (Japanese).</mixed-citation></ref><ref id="jdi12361-bib-0005"><label>5</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sadosky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McDermott</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Brandenburg</surname>
<given-names>NA</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions</article-title>. <source>Pain Pract</source>
<year>2008</year>; <volume>8</volume>: <fpage>45</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">18211592</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0006"><label>6</label><mixed-citation publication-type="journal">
<string-name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Vinik</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Arezzo</surname>
<given-names>JC</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Diabetic neuropathies: a statement by the American Diabetes Association</article-title>. <source>Diabetes Care</source>
<year>2005</year>; <volume>28</volume>: <fpage>956</fpage>&#x02013;<lpage>962</lpage>.<pub-id pub-id-type="pmid">15793206</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0007"><label>7</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gore</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brandenburg</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Dukes</surname>
<given-names>E</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep</article-title>. <source>J Pain Symptom Manage</source>
<year>2005</year>; <volume>30</volume>: <fpage>374</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">16256902</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0008"><label>8</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jensen</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Chodroff</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Dworkin</surname>
<given-names>RH</given-names>
</string-name>. <article-title>The impact of neuropathic pain on health&#x02010;related quality of life: review and implications</article-title>. <source>Neurology</source>
<year>2007</year>; <volume>68</volume>: <fpage>1178</fpage>&#x02013;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">17420400</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0009"><label>9</label><mixed-citation publication-type="journal">
<string-name>
<surname>Zelman</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Brandenburg</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Gore</surname>
<given-names>M</given-names>
</string-name>. <article-title>Sleep impairment in patients with painful diabetic peripheral neuropathy</article-title>. <source>Clin J Pain</source>
<year>2006</year>; <volume>22</volume>: <fpage>681</fpage>&#x02013;<lpage>685</lpage>.<pub-id pub-id-type="pmid">16988563</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0010"><label>10</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tesfaye</surname>
<given-names>S</given-names>
</string-name>. <article-title>Recent advances in the management of diabetic distal symmetrical polyneuropathy</article-title>. <source>J Diabetes Investig</source>
<year>2011</year>; <volume>2</volume>: <fpage>33</fpage>&#x02013;<lpage>42</lpage>.</mixed-citation></ref><ref id="jdi12361-bib-0011"><label>11</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tesfaye</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vileikyte</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rayman</surname>
<given-names>G</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management</article-title>. <source>Diabetes Metab Res Rev</source>
<year>2011</year>; <volume>27</volume>: <fpage>629</fpage>&#x02013;<lpage>638</lpage>.<pub-id pub-id-type="pmid">21695762</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0012"><label>12</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lustman</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Griffith</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Clouse</surname>
<given-names>RE</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Effects of nortriptyline on depression and glycemic control in diabetes: results of a double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Psychosom Med</source>
<year>1997</year>; <volume>59</volume>: <fpage>241</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">9178335</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0013"><label>13</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ray</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Meredith</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thapa</surname>
<given-names>PB</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Cyclic antidepressants and the risk of sudden cardiac death</article-title>. <source>Clin Pharmacol Ther</source>
<year>2004</year>; <volume>75</volume>: <fpage>234</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">15001975</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0014"><label>14</label><mixed-citation publication-type="journal">
<string-name>
<surname>Zimmermann</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kraus</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Himmerich</surname>
<given-names>H</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Epidemiology, implications and mechanisms underlying drug&#x02010;induced weight gain in psychiatric patients</article-title>. <source>J Psychiatr Res</source>
<year>2003</year>; <volume>37</volume>: <fpage>193</fpage>&#x02013;<lpage>220</lpage>.<pub-id pub-id-type="pmid">12650740</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0015"><label>15</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bymaster</surname>
<given-names>FP</given-names>
</string-name>, <string-name>
<surname>Dreshfield&#x02010;Ahmad</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Threlkeld</surname>
<given-names>PG</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in&#x000a0;vitro and in&#x000a0;vivo, human serotonin receptor subtypes, and other neuronal receptors</article-title>. <source>Neuropsychopharmacology</source>
<year>2001</year>; <volume>25</volume>: <fpage>871</fpage>&#x02013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">11750180</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0016"><label>16</label><mixed-citation publication-type="journal">
<string-name>
<surname>Boyle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Gribble</surname>
<given-names>L</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Randomized, placebo&#x02010;controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life</article-title>. <source>Diabetes Care</source>
<year>2012</year>; <volume>35</volume>: <fpage>2451</fpage>&#x02013;<lpage>2458</lpage>.<pub-id pub-id-type="pmid">22991449</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0017"><label>17</label><mixed-citation publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Detke</surname>
<given-names>MJ</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Duloxetine vs. placebo in patients with painful diabetic neuropathy</article-title>. <source>Pain</source>
<year>2005</year>; <volume>116</volume>: <fpage>109</fpage>&#x02013;<lpage>118</lpage>.<pub-id pub-id-type="pmid">15927394</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0018"><label>18</label><mixed-citation publication-type="journal">
<string-name>
<surname>Raskin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pritchett</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>F</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A double&#x02010;blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain</article-title>. <source>Pain Med</source>
<year>2005</year>; <volume>6</volume>: <fpage>346</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">16266355</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0019"><label>19</label><mixed-citation publication-type="journal">
<string-name>
<surname>Skljarevski</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Frakes</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Sagman</surname>
<given-names>D</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Review of efficacy and safety of duloxetine 40 to 60 mg once daily in patients with diabetic peripheral neuropathic pain</article-title>. <source>Pain Res Treat</source>
<year>2012</year>; <volume>2012</volume>: <fpage>898347</fpage>.<pub-id pub-id-type="pmid">22973509</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0020"><label>20</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tanenberg</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Irving</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Risser</surname>
<given-names>RC</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open&#x02010;label, randomized, noninferiority comparison</article-title>. <source>Mayo Clin Proc</source>
<year>2011</year>; <volume>86</volume>: <fpage>615</fpage>&#x02013;<lpage>626</lpage>.<pub-id pub-id-type="pmid">21719618</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0021"><label>21</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wernicke</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Pritchett</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>D'Souza</surname>
<given-names>DN</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain</article-title>. <source>Neurology</source>
<year>2006</year>; <volume>67</volume>: <fpage>1411</fpage>&#x02013;<lpage>1420</lpage>.<pub-id pub-id-type="pmid">17060567</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0022"><label>22</label><mixed-citation publication-type="journal">
<string-name>
<surname>Yasuda</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hotta</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>K</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan</article-title>. <source>J Diabetes Investig</source>
<year>2011</year>; <volume>2</volume>: <fpage>132</fpage>&#x02013;<lpage>138</lpage>.</mixed-citation></ref><ref id="jdi12361-bib-0023"><label>23</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wernicke</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pritchett</surname>
<given-names>YL</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>An open&#x02010;label 52&#x02010;week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain</article-title>. <source>Pain Med</source>
<year>2007</year>; <volume>8</volume>: <fpage>503</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">17716324</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0024"><label>24</label><mixed-citation publication-type="journal">
<string-name>
<surname>Raskin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>K</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Duloxetine versus routine care in the long&#x02010;term management of diabetic peripheral neuropathic pain</article-title>. <source>J Palliat Med</source>
<year>2006</year>; <volume>9</volume>: <fpage>29</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">16430342</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0025"><label>25</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hall</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Oakes</surname>
<given-names>TM</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo&#x02010;controlled clinical trials</article-title>. <source>Expert Opin Drug Saf</source>
<year>2010</year>; <volume>9</volume>: <fpage>525</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">20465525</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0026"><label>26</label><mixed-citation publication-type="journal">
<collab collab-type="authors">Diabetic Neuropathy Study Group</collab>
. <article-title>Abbreviated diagnostic criteria for distal symmetric polyneuropathy</article-title>. <source>Peripher Nerv</source>
<year>2003</year>; <volume>14</volume>: <fpage>225</fpage> (Japanese).</mixed-citation></ref><ref id="jdi12361-bib-0027"><label>27</label><mixed-citation publication-type="journal">
<string-name>
<surname>Cleeland</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>KM</given-names>
</string-name>. <article-title>Pain assessment: global use of the brief pain inventory</article-title>. <source>Ann Acad Med Singapore</source>
<year>1994</year>; <volume>23</volume>: <fpage>129</fpage>&#x02013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">8080219</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0028"><label>28</label><mixed-citation publication-type="book">
<string-name>
<surname>Guy</surname>
<given-names>W</given-names>
</string-name>. <source>ECDEU Assessment Manual for Psychopharmacology, Revised</source>. <publisher-name>US Department of Health, Education, and Welfare Publication, National Institute of Mental Health</publisher-name>, <publisher-loc>Rockville</publisher-loc>, <year>1976</year>; <fpage>129</fpage>&#x02013;<lpage>138</lpage>.</mixed-citation></ref><ref id="jdi12361-bib-0029"><label>29</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kashiwagi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kasuga</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Araki</surname>
<given-names>E</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values</article-title>. <source>J Diabetes Investig</source>
<year>2012</year>; <volume>3</volume>: <fpage>39</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="jdi12361-bib-0030"><label>30</label><mixed-citation publication-type="journal">
<string-name>
<surname>Raskin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pritchett</surname>
<given-names>YL</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Duloxetine for patients with diabetic peripheral neuropathic pain: a 6&#x02010;month open&#x02010;label safety study</article-title>. <source>Pain Med</source>
<year>2006</year>; <volume>7</volume>: <fpage>373</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">17014595</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous">
<collab collab-type="authors">National Institute for Health and Clinical Excellence (NICE)</collab>
. <article-title>Short Clinical Guideline 87</article-title>. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0033486/">http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0033486/</ext-link>. Effective May 2009. Accessed 13 March 2013.</mixed-citation></ref><ref id="jdi12361-bib-0032"><label>32</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hardy</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sachson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>S</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Does treatment with duloxetine for neuropathic pain impact glycemic control?</article-title>
<source>Diabetes Care</source>
<year>2007</year>; <volume>30</volume>: <fpage>21</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">17192327</pub-id></mixed-citation></ref><ref id="jdi12361-bib-0033"><label>33</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wasan</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Ossanna</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Raskin</surname>
<given-names>J</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients</article-title>. <source>Curr Drug Saf</source>
<year>2009</year>; <volume>4</volume>: <fpage>22</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">19149522</pub-id></mixed-citation></ref></ref-list></back></article>